The invention relates to a biomarker for
cholestasis indication prognosis, a marker detection method and a corresponding kit. The prognosis indication biomarker is selected from one or more of glycyl acylated
hyocholic acid (Glyco-hyoCA or GHCA), taurosylated-2 [beta], 3 [alpha], 7 [alpha], 12 [alpha]-tetrahydroxycholic acid (Tauro-2 [beta], 3 [alpha], 7 [alpha], 12 [alpha]-Tetraphydroxy bileacid or Tauro-2 [beta], 3 [alpha], 7 [alpha], 12 [alpha]-THBA),taurosylated
hyocholic acid (Tauro-hyoCA or THCA), Tauro-3 [alpha], 6 [beta], 7 [alpha], 12 [alpha]-THBA, Tauro-3 [alpha], 6 [alpha], 7 [alpha], 12 [alpha]-THBA, and total Tauro-THBAs. The detection finds that
bile acid spectrums in serum /
plasma samples of subjects are concentrated, different bile acids are screened out to serve as candidate indication prognosis markers, meanwhile, corresponding cutoff values are formulated, and the cutoff values are applied to a
verification set to verify the indication prognosis efficiency of the
verification set. The invention provides the method and the kit for prognosis judgment of
cholestasis for the first time, the detection efficiency is high, the result is accurate, the method and the kit are suitable for early prognosis effect judgment of patients with
cholestasis, and guidance is provided for individual treatment and medication schemes.